131 related articles for article (PubMed ID: 37714008)
1. Connecting patients notified with hepatitis C to treatment (CONNECT Study): A randomized controlled trial of active case management by a health department to support primary care practitioners.
Marukutira T; Barter R; Moore KP; Hellard ME; Richmond J; Turner K; Pedrana AE; Melody S; Johnston FH; Owen L; Boom WVD; Scott N; Thompson A; Iser DM; Spelman T; Veitch M; Stoové M; Doyle JS
Int J Drug Policy; 2023 Nov; 121():104184. PubMed ID: 37714008
[TBL] [Abstract][Full Text] [Related]
2. Randomised controlled trial of active case management to link hepatitis C notifications to treatment in Tasmania, Australia: a study protocol.
Marukutira T; Moore KP; Hellard M; Richmond J; Turner K; Pedrana AE; Melody S; Johnston FH; Owen L; Van Den Boom W; Scott N; Thompson A; Iser D; Spelman T; Veitch M; Stoové MA; Doyle J
BMJ Open; 2022 Mar; 12(3):e056120. PubMed ID: 35338062
[TBL] [Abstract][Full Text] [Related]
3. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
[TBL] [Abstract][Full Text] [Related]
4. Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis.
Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Valencia BM; Bajis S; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
Lancet Gastroenterol Hepatol; 2022 May; 7(5):426-445. PubMed ID: 35303490
[TBL] [Abstract][Full Text] [Related]
5. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial for a peer-facilitated telemedicine hepatitis c treatment intervention for people who use drugs in rural communities: study protocol for the "peer tele-HCV" study.
Herink MC; Seaman A; Leichtling G; Larsen JE; Gailey T; Cook R; Thomas A; Korthuis PT
Addict Sci Clin Pract; 2023 May; 18(1):35. PubMed ID: 37245041
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ
J Viral Hepat; 2019 Aug; 26(8):969-979. PubMed ID: 30980785
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs.
Wade AJ; Doyle JS; Gane E; Stedman C; Draper B; Iser D; Roberts SK; Kemp W; Petrie D; Scott N; Higgs P; Agius PA; Roney J; Stothers L; Thompson AJ; Hellard ME
Clin Infect Dis; 2020 Apr; 70(9):1900-1906. PubMed ID: 31233117
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study.
Hosseini-Hooshyar S; Alavi M; Martinello M; Valerio H; Tillakeratne S; Matthews GV; Dore GJ
J Viral Hepat; 2022 Apr; 29(4):271-279. PubMed ID: 35175671
[TBL] [Abstract][Full Text] [Related]
10. Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia.
Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891474
[TBL] [Abstract][Full Text] [Related]
11. "It's time!": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C.
Walker S; Wallace J; Latham N; Saich F; Pedrana A; Hellard M; Treloar C; Marukutira T; Higgs P; Doyle J; Stoové M
Int J Drug Policy; 2021 Nov; 97():103280. PubMed ID: 34058670
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study.
Yousafzai MT; Alavi M; Valerio H; Hajarizadeh B; Grebely J; Dore GJ
J Viral Hepat; 2023 Mar; 30(3):250-261. PubMed ID: 36537024
[TBL] [Abstract][Full Text] [Related]
13. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
Doyle JS; Scott N; Sacks-Davis R; Pedrana AE; Thompson AJ; Hellard ME;
Aliment Pharmacol Ther; 2019 May; 49(9):1223-1229. PubMed ID: 30908706
[TBL] [Abstract][Full Text] [Related]
14. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G
BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
16. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
[TBL] [Abstract][Full Text] [Related]
17. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of community-based hepatitis C treatment by general practitioners and nurses in Australia through remote specialist consultation.
Haridy J; Iyngkaran G; Nicoll A; Muller K; Wilson M; Wigg A; Ramachandran J; Nelson R; Bloom S; Sasadeusz J; Watkinson S; Colman A; Altus R; Tilley E; Stewart J; Hebbard G; Liew D; Tse E
Intern Med J; 2021 Nov; 51(11):1927-1934. PubMed ID: 32892478
[TBL] [Abstract][Full Text] [Related]
19. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
20. A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia.
Harney BL; Whitton B; Paige E; Brereton R; Weiss R; Membrey D; Wade AJ; Iser D; Kemp W; Roberts SK; Spelman T; Sacks-Davis R; Hellard ME; Doyle JS
Liver Int; 2022 Mar; 42(3):522-531. PubMed ID: 34821021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
